A detailed history of Ubs Group Ag transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 33,791 shares of ACRS stock, worth $70,623. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,791
Previous 70,401 52.0%
Holding current value
$70,623
Previous $87,000 57.47%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.01 - $1.36 $36,976 - $49,789
-36,610 Reduced 52.0%
33,791 $37,000
Q1 2024

May 13, 2024

BUY
$0.92 - $1.44 $46,714 - $73,118
50,777 Added 258.75%
70,401 $87,000
Q4 2023

Feb 09, 2024

SELL
$0.64 - $6.49 $20,514 - $208,030
-32,054 Reduced 62.03%
19,624 $20,000
Q3 2023

Nov 09, 2023

BUY
$6.56 - $10.95 $320,547 - $535,060
48,864 Added 1736.46%
51,678 $353,000
Q2 2023

Aug 11, 2023

BUY
$7.89 - $10.64 $6,162 - $8,309
781 Added 38.42%
2,814 $29,000
Q1 2023

May 12, 2023

SELL
$7.07 - $17.95 $2,637 - $6,695
-373 Reduced 15.5%
2,033 $16,000
Q4 2022

Feb 08, 2023

SELL
$14.33 - $18.37 $6,663 - $8,542
-465 Reduced 16.2%
2,406 $37,000
Q3 2022

Nov 10, 2022

BUY
$13.07 - $18.22 $6,077 - $8,472
465 Added 19.33%
2,871 $45,000
Q2 2022

Aug 10, 2022

BUY
$10.16 - $17.08 $7,152 - $12,024
704 Added 41.36%
2,406 $34,000
Q1 2022

May 16, 2022

SELL
$9.74 - $17.92 $433,293 - $797,189
-44,486 Reduced 96.32%
1,702 $29,000
Q4 2021

Feb 14, 2022

BUY
$12.27 - $18.49 $546,481 - $823,507
44,538 Added 2699.27%
46,188 $671,000
Q3 2021

Nov 15, 2021

SELL
$13.38 - $18.8 $16,711 - $23,481
-1,249 Reduced 43.08%
1,650 $30,000
Q2 2021

Aug 13, 2021

SELL
$17.08 - $29.6 $59,216 - $102,623
-3,467 Reduced 54.46%
2,899 $51,000
Q1 2021

May 12, 2021

BUY
$5.86 - $27.73 $29,651 - $140,313
5,060 Added 387.44%
6,366 $160,000
Q4 2020

Feb 11, 2021

SELL
$2.65 - $7.61 $9,831 - $28,233
-3,710 Reduced 73.96%
1,306 $8,000
Q3 2020

Nov 12, 2020

BUY
$1.5 - $2.71 $6,703 - $12,110
4,469 Added 817.0%
5,016 $13,000
Q2 2020

Jul 31, 2020

SELL
$1.04 - $1.73 $19,188 - $31,918
-18,450 Reduced 97.12%
547 $1,000
Q1 2020

May 01, 2020

SELL
$0.75 - $2.18 $14,106 - $41,003
-18,809 Reduced 49.75%
18,997 $20,000
Q4 2019

Feb 14, 2020

BUY
$1.02 - $1.97 $29,323 - $56,635
28,749 Added 317.42%
37,806 $71,000
Q3 2019

Nov 14, 2019

SELL
$0.79 - $2.47 $716,921 - $2.24 Million
-907,495 Reduced 99.01%
9,057 $10,000
Q2 2019

Aug 14, 2019

BUY
$2.13 - $7.06 $496,317 - $1.65 Million
233,013 Added 34.09%
916,552 $2.01 Million
Q1 2019

May 14, 2019

SELL
$5.63 - $7.84 $3.57 Million - $4.97 Million
-633,721 Reduced 48.11%
683,539 $4.09 Million
Q4 2018

Feb 14, 2019

BUY
$6.3 - $15.4 $8.3 Million - $20.3 Million
1,317,241 Added 6932847.5%
1,317,260 $9.73 Million
Q2 2018

Aug 14, 2018

SELL
$16.46 - $20.33 $39,734 - $49,076
-2,414 Reduced 99.22%
19 $0
Q1 2018

May 15, 2018

SELL
$17.08 - $25.64 $4,440 - $6,666
-260 Reduced 9.65%
2,433 $43,000
Q4 2017

Feb 14, 2018

SELL
$21.47 - $27.8 $72,182 - $93,463
-3,362 Reduced 55.52%
2,693 $66,000
Q3 2017

Nov 14, 2017

BUY
$23.02 - $28.8 $63,719 - $79,718
2,768 Added 84.21%
6,055 $156,000
Q2 2017

Aug 14, 2017

SELL
N/A
-1,175 Reduced 26.33%
3,287 $90,000
Q1 2017

Nov 14, 2017

BUY
N/A
4,462
4,462 $133,000

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $139M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.